|Conditional recommendation based on low-quality evidence; may consider abatacept if the patient had a primary TNFi biologic efficacy failure or TNFi biologic–associated serious adverse effect.| |
|4. Switch to a different TNFi biologic over switching to tofacitinib (PICO 73)|Low (62–66, 72–78, 105)|